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ABSTRACT
Approximately 15% of human genetic diseases are
estimated to involve dysregulation of alternative
pre-mRNA splicing. Antisense molecules designed
to alter these and other splicing events typically
target continuous linear sequences of the
message. Here, we show that a structural feature
in a pre-mRNA can be targeted by bipartite anti-
sense molecules designed to hybridize with the dis-
continuous elements that flank the structure and
thereby alter splicing. We targeted a hairpin struc-
ture at the boundary between exon 10 and intron 10
of the pre-mRNA of tau. Mutations in this region that
are associated with certain forms of frontotemporal
dementia, destabilize the hairpin to cause increased
inclusion of exon 10. Via electrophoretic mobility
shift and RNase protection assays, we demonstrate
that bipartite antisense molecules designed to sim-
ultaneously interact with the available sequences
that immediately flank the tau pre-mRNA hairpin
do indeed bind to this structured region. Moreover,
these agents inhibit exon 10 splicing and reverse the
effect of destabilizing disease-causing mutations, in
both in vitro splicing assays and cell culture. This
general bipartite antisense strategy could be
employed to modulate other splicing events that
are regulated by RNA secondary structure.
INTRODUCTION
In general, alternative RNA splicing is a major source of
proteomic diversity. Over 90% of human genes are alter-
natively spliced (1), with even more alternative splicing
occurring in the human brain (2), and an estimated 15%
of disease-causing mutations alter splicing (3). There is a
growing awareness that structural features in the
pre-mRNA can play an important role in determining
alternative splicing events (4,5). The presence of such
structures at or near splice sites provides opportunities
for the design of agents that target these features and
regulate speciﬁc splicing events. Such agents should help
contribute both to the basic understanding of splice regu-
lation in biology and to the development of practical
therapeutics for diseases in which speciﬁc splicing events
are dysregulated or where shunting splicing toward par-
ticular isoforms would be otherwise beneﬁcial. The idea of
developing agents to alter speciﬁc RNA splicing events by
targeting structural features in the message is virtually
unexplored.
As a proof of principle for this approach, we have
chosen to target the pre-mRNA of the microtubule-
associated protein tau. Assembly of the tau protein into
intraneuronal ﬁlaments is a primary pathological feature
of a spectrum of neurodegenerative diseases, including
Alzheimer’s disease and frontotemporal dementia (FTD)
(6). Some 40 mutations in the tau gene are associated with
autosomal-dominant familial FTD, and many of these are
silent or intronic mutations that shift the splicing of the
tau pre-mRNA in favor of inclusion of exon 10 (7). This
exon encodes for one of four possible repeated microtu-
bule binding domains, with exclusion leading to a 3-repeat
form (3R tau) and inclusion leading to the 4-repeat form
(4R tau). A hairpin structure is located at the junction
between exon 10 and intron 10. FTD mutations found
in this region destabilize the hairpin and increase the pro-
portion of splicing that leads to 4R tau (8–10). In contrast,
artiﬁcial stabilizing mutations decrease exon 10 inclusion
(11). Moreover, the degree of exon 10 exclusion correlates
with the experimentally determined melting temperatures
of hairpin oligonucleotide variants based on the exon 10/
intron 10 junction (11).
To target this hairpin structure, we designed bipartite
antisense oligonucleotides (ASOs) that would simultan-
eously interact with the 50- and 30-regions that immediately
ﬂank this structure. As the two parts of the ASO are held
together in a single molecule, binding of the bipartite ASO
should occur even in the presence of the structure and
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bind simultaneously to both ﬂanking sequences and spe-
ciﬁcally reduce inclusion of exon 10 of tau mRNA, both
in vitro and in cells, with a tau minigene system, as well as
endogenous tau.
MATERIALS AND METHODS
Electrophoretic mobility shift assay
RNA oligonucleotides were purchased from Dharmacon
(part of Thermo Scientiﬁc). DNA oligonucleotides were
purchased from Invitrogen. Prior to hybridization, RNA
representing the tau hairpin and ﬂanking sequences
(sequence 50-GGGAGGCGGCAGUGUGAGUACCUU
CACACGUCCCAUGCGC-30) or the mutated tau
hairpin and ﬂanking sequences (sequence 50-GGGAGGC
GGAAUCUCUUGUACCUUCACACGUCCCAUGCG
C-30) was renatured by heating to 80 C for 5min and then
cooling slowly to 25 C over 30min. 0.5mM
hairpin-containing RNA was hybridized with 0.5mM
ASO in incubation buffer at 25 C for 30min (50mM
TRIS–HCl, pH 7.5, 10mM MgCl2, 10mM NaCl,
0.1mM EDTA). Novex hi-density Tris/borate/EDTA
(TBE) sample buffer was added to the sample and hybrid-
ization was analyzed by 15% acrylamide gel electrophor-
esis in TRIS–borate–EDTA buffer (89mM TRIS Base,
89mM boric acid, 2mM EDTA). The acrylamide gel and
running buffer were pre-cooled to 4 C, and the samples
were electrophoresed at 4 C. Bands were visualized by
SYBR Gold staining (Invitrogen) under UV light, and
images were captured with an AlphaImager system.
Synthesis of bipartite peptide nucleic acid oligomers
Peptide nucleic acid (PNA) oligomers were synthesized
on Rink Amide PEGA resin (Novabiochem).
Octa(L-lysine) peptide was covalently assembled on the
PNA N-end as a cell penetrating peptide. PNA
monomers (Fmoc/Bhoc protected) were commercially
available (Link Technologies, UK). The monomer N-
Fmoc-egl-OH (Sigma-Aldrich) was used to build the
linker for bipartite PNA. Fmoc deprotection was carried
out using 20% piperidine in dimethyl formamide (DMF).
Amide coupling was performed using the coupling agent
HATU. Final cleavage and deprotection were carried out
with TFA/m-cresol solution. The crude PNA product
cleaved from resin was conﬁrmed to be pure by
reverse-phase high pressure liquid chromatography
(RP–HPLC), characterized by matrix-assisted laser
desorption-time of ﬂight (MALDI-TOF) mass spectrom-
etry and used directly without further puriﬁcation. The
PNA aqueous solutions were prepared, and the concen-
trations were determined by the UV absorbance at 260nm
on a SPECTRAmax PLUS 384 spectrophotometer.
RNase A and T1 protection assays
50-biotinylated hairpin-containing RNA (sequence as
above) was renatured in structure buffer (10mM TRIS
pH 7.0, 100mM KCl, 10mM MgCl2) by heating to 80 C
for 5min and cooling to 25 C over 30min. Streptavidin
agarose beads (Sigma) were washed twice in structure
buffer, and 0.8mg of renatured biotinylated
hairpin-containing RNA was bound to the beads for
30min at 25 C on a rotator. An equimolar concentration
of complementary DNA (9-2A-10) was added, where
indicated and allowed to bind for 20min at 25 C. RNase
A or T1 was added, and the reaction was allowed to
proceed for 10min at 37 C. Final concentrations in the
RNase reaction were 10mM hairpin-containing RNA,
10mM 9-2A-10, 1mU/ml RNase A or 100 mU/ml RNase
T1. Beads were washed twice in urea buffer at 50 Ct o
remove cleaved 30-fragments (20mM sodium citrate pH
5.0, 1mM EDTA, 7M urea). 50-biotinylated fragments
were then eluted from the beads by heating for 5min at
95 C in loading buffer II (Ambion). Samples were
analyzed by denaturing acrylamide gel electrophoresis
(20% acrylamide, 7M urea) in TBE buffer, alongside a
ladder of all possible 50-biotinylated cleavage fragments
produced by alkaline hydrolysis. Cleavage fragments
were visualized by SYBR Gold staining under UV light.
RNase H digestion
Complementary DNA oligonucleotides were hybridized to
the hairpin-containing RNA (10mM each) in structure
buffer. The hybrids were then diluted to 1mM in HEPES
buffer (20mM HEPES–KOH, pH 8.0, 50mM KCl, 4mM
MgCl2, 1mM DTT, 50mg/ml BSA) containing RNase H
(ﬁnal concentrations of 1mM hairpin-containing RNA,
1mM complementary DNA, 1% vol/vol RNase H,
Sigma). Samples were incubated at 37 C for 20min to
allow digestion of RNA in RNA:DNA hybrids by
RNase H. Loading buffer II was added, and samples
were heated for 5min at 95 C before analyzing by
denaturing acrylamide gel electrophoresis (20% acryl-
amide, 7 M urea). RNA and DNA bands were visualized
by SYBR Gold staining under UV light.
In vitro splicing assay
HeLa nuclear extract was prepared by a method adapted
from Dignam et al. (12). In order to generate the splicing
unit RNA, tau exon 10, the ﬁrst 207 bases of intron 10, the
last 213 bases of intron 10 and exon 11 were ampliﬁed
from HEK-293 cell genomic DNA by In-Fusion PCR
(Clontech), and cloned into pcDNA3.1/Zeo(+)
(Invitrogen) between BamHI and XhoI sites. The insert
was conﬁrmed by sequencing. The vector was then
linearized by digestion with XbaI, and the insert was
transcribed into RNA in vitro using Ambion’s
MEGAscript T7 kit. In vitro splicing reactions were per-
formed for 3h at 30 C in reaction volumes of 25ml.
Reactions contained 20fmol splicing unit RNA, 0 1mM
RNA ASO, 10ml HeLa nuclear extract, 20mM phospho-
creatine, 0.5mM ATP, 3.2mM MgCl2, 40 mU/ml creatine
phosphokinase and 2.6% vol/vol polyvinyl alcohol in
buffer D [20mM HEPES–KOH, pH 8.0, 100mM KCl,
0.2mM EDTA, 20% (vol/vol) glycerol, 0.5mM PMSF,
1mM DTT]. In negative control reactions, HeLa nuclear
extract was substituted with extra buffer D. Spliced
products were puriﬁed by phenol/chloroform precipitation
and treated with DNase. Spliced products were ampliﬁed
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splicing unit RNA (pcDNA3f and tauE11 r), and
analyzed by 8% acrylamide gel electrophoresis in TBE
buffer with SYBR Gold staining under UV light.
Minigenes and cell transfections
The tau minigene used was as previously described (11),
and comprised exons 9, 10 and 11 with shortened
intervening introns cloned into the pcDNA3 vector
(Invitrogen). The coding region for the photinus pyralis
luciferase gene was ligated after exon 11 to provide a
sequence for a reverse PCR primer unique to the
minigene so as not to detect endogenous tau. The
BACE1 minigene was comprised of exon 3, intron 3 and
exon 4 truncated prior to the alternative 30-splice site (13).
The 5X stem mutant tau minigene was generated from the
wild-type tau minigene using the QuikChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies) ac-
cording to the manufacturer’s protocol. Primer sequences
are shown in Supplementary Table S1 (nucleotide changes
are italicized). Other minigenes were as previously
described (14). HeLa, HEK-293 and SK-N-SH cells were
grown in DMEM containing 4.5mg/ml glucose, supple-
mented with 10% fetal bovine serum, 2mM glutamine,
50U/ml penicillin and 50mg/ml streptomycin. For
exon-trapping PCR experiments, SK-N-SH cells were
seeded into 12-well plates and co-transfected at 80–90%
conﬂuence with 0.25mg minigene plasmid DNA and
10nM antisense RNA, using 4ml lipofectamine per well.
For real-time PCR experiments to investigate the effect of
antisense RNA on the tau minigene, SK-N-SH cells were
co-transfected at 80–90% conﬂuence with 0.25mg tau
minigene, 0.05mg pRL-TK vector (transfection control,
Promega) and 0–100nM antisense RNA, using 4ml
lipofectamine per well. For real-time PCR experiments
to investigate the effect of antisense on the endogenous
tau pre-mRNA, HEK-293 cells were seeded into plates
coated with poly-D-lysine and transfected at 50% conﬂu-
ence with 0–1mM RNA antisense, using 4.5ml
oligofectamine per well. The sequences of all antisense
RNA oligonucleotides used are shown in Table 1.
Reverse transcription and exon-trapping PCR
RNA was isolated 24h after transfection using Ambion’s
RNAqueous
TM kit according to the manufacturer’s
protocol. RNA was quantiﬁed, and 1.5–2mg was reverse
transcribed into cDNA using Ambion’s RETROscript
TM
kit with oligo(dT) primer. Exon-trapping PCR was per-
formed for 30 cycles using SuperTaq
TM polymerase
(Ambion) and 2.5ml cDNA in a 25ml reaction. For
exon-trapping PCR from the tau minigene, a forward
primer in exon 9 (tau E9 f) and a reverse primer in the
luciferase coding region of the tau minigene (luciferase r)
were used. For exon-trapping PCR from the BACE1
minigene, a forward primer in exon 3 (BACE E3 f) and
a reverse primer in the bovine growth hormone sequence
of the pcDNA vector (pcDNA3 BGHr) were used.
Sequences of all primers are shown in Supplementary
Table S1. PCR products were separated by 8% acrylamide
gel electrophoresis alongside Bioline Hyperladder V, and
visualized by SYBR Gold staining under UV light.
Quantitative PCR and data analysis
RNA was isolated from transfected cells and reverse
transcribed into cDNA as described above. Quantitative
PCR was performed using an Applied Biosystems 7500
Real-Time PCR Fast System with SYBR Green PCR
mastermix (Invitrogen). PCR reactions were performed
at 64 C for a combined annealing and extension. 3R tau
from the minigene was ampliﬁed using tau E9-E11 f and
luciferase r; 4R tau from the minigene was ampliﬁed using
tau E9-E10 f and luciferase r; total tau from the minigene
was ampliﬁed using luciferase f and luciferase r2.
Endogenous 3R tau was ampliﬁed using tau E9-E11 f
and tau E11 r; endogenous 4R tau was ampliﬁed using
tau E9-E10 f and tau E11 r and total endogenous tau
was ampliﬁed using total tau f and r (both in exon 9).
Primer sequences are shown in Supplementary Table S1.
Data were analyzed using Sequence Detection System
software according to the Ct method, where the ex-
pression of 3R and 4R tau was normalized to pRL-TK (a
transfection control for the tau minigene) or to total tau
(endogenous tau experiments), and the expression of total
tau was normalized to either pRL-TK (minigene experi-
ments) or to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (endogenous tau experiments). Experiments
were repeated on at least two separate occasions with rep-
licates of three or more within each experiment. Graphs
were drawn and statistical tests were carried out using
GraphPad Prism; signiﬁcant differences were determined
using one-way ANOVA with the Bonferoni post-hoc test
(*P<0.05, **P<0.01, ***P<0.001).
RESULTS
Bipartite ASOs bind to a synthetic tau RNA
oligonucleotide
Our ﬁrst designed bipartite ASOs were DNAs with up to
10 bases on either side, complementary to their respective
partner regions that ﬂank the stem–loop (or hairpin)
structure at the tau pre-mRNA exon 10–intron 10
junction (Figure 1A). The DNA ASOs have 1, 2 or 3 ad-
enosine spacers to bridge any potential gap between the
ﬂanking sequences (i.e. to ensure that both complemen-
tary parts can bind simultaneously). Adenosine was
chosen because there are no complementary uridines at
the base of the stem. To determine whether DNA bipartite
ASOs could bind to the discontinuous region at the base
of the tau hairpin, electrophoretic mobility shift assays
(EMSA) were performed. An EMSA gel (Figure 1B)
revealed that DNA with 9 bases complementary to the
50-ﬂank, a linker of one adenosine, and 10 bases comple-
mentary to the 30-ﬂank (termed 9-1A-10 DNA; Table 1
lists all ASOs used in this study) can hybridize virtually
completely to a synthetic 40-nt tau hairpin-containing
RNA at equimolar concentrations, as shown by a band
of slower mobility (lane 3) compared with tau RNA alone
(lane 1). Similar experiments in which the concentrations
of DNA ASO were varied further supported a 1:1 binding
9838 Nucleic Acids Research, 2012,Vol.40, No. 19ratio (Supplementary Figure S1). Linkers of two or three
adenosines also allowed complete hybridization (lanes 5
and 7). In light of this, we tested the comparable DNA
ASO with no linker adenosine and found that it hybridizes
equally well (Supplementary Figure S2). A DNA ASO
designed against the continuous, linear sequence at the
exon 10–intron 10 junction (21 nts, from G 7 to A+13)
also hybridized to the RNA (lane 9), although binding was
not complete, with bands representing the tau RNA alone
and the DNA ASO still observed. The complete binding of
DNAs 9-1A-10, 9-2A-10 and 9-3A-10 to the discontinuous
regions ﬂanking the tau hairpin suggests that the equilib-
rium lies in favor of the hairpin structure over unfolded
RNA under these assay conditions. DNA with a
scrambled sequence did not bind the tau RNA (lane 11).
Binding of ASOs directed to the 50-o r3 0-ﬂank separ-
ately was also assessed using EMSA (Figure 1C). Addition
of an ASO directed to the 50-ﬂank resulted in mobility
shift (lane 3) but surprisingly, the 10 nucleotide ASO
directed to the 30-ﬂank did not bind. When DNA ASOs
against the 50- and 30-ﬂanks were assessed together, the
mobility of the hybrid is equivalent to that of the tau
RNA bound to the 50-ﬂank DNA ASO alone. However,
the 30-ﬂank-directed portion does play a role in binding of
bipartite DNA ASO across the discontinuous region
(Figure 1D). Bipartite DNA ASO 7-2A-7 does not hybrid-
ize (lane 2), nor does DNA 8-2A-0 (lane 3). By increasing
the length of the region complementary to the 30-ﬂank in
steps of one nucleotide, we see that 8-2A-1, 8-2A-2,
8-2A-3, 8-2A-4 and 8-2A-5 are not sufﬁcient for binding
(lanes 4–8). Interestingly, the DNA bands representing
8-2A-0 and 8-2A-1 (lanes 3 and 4) are not detected
under these EMSA conditions due to their small size.
However, they are not hybridized to the hairpin RNA
since there is no mobility shift of the RNA in these
lanes. In contrast, 8-2A-6, 8-2A-7 and 8-2A-8 bind effect-
ively, resulting in a hybrid with slower electrophoretic
mobility (lanes 9–11). This result indicates that the
portion of the bipartite ASO directed to the 30-ﬂank is
indeed involved in binding over this discontinuous
region. Further evidence of binding to the 30-ﬂank is
provided below using nuclease digestion.
In addition to DNA ASOs, RNA ASOs were tested for
hybridization to the tau hairpin-containing RNA by
EMSA. The RNA ASOs were modiﬁed with 20-OMe
groups and a phosphorothioate backbone to confer stabil-
ity against nucleases, as these ASOs were also used to study
splicing in cells in later experiments. Like their DNA coun-
terparts, RNA ASOs 9-1A-10, 9-2A-10 and 9-3A-10
hybridized to the tau RNA, and linker length did not
Table 1. Synthetic DNA, RNA and PNA antisense molecules used in this study
9-1A-10 DNA 50-GCGCATGGGAACCGCCTCCC-30
9-2A-10 DNA 50-GCGCATGGGAAACCGCCTCCC-30
9-3A-10 DNA 50-GCGCATGGGAAAACCGCCTCCC-30
Linear DNA 50-TGAAGGTACTCACACTGCCGC-30
Scrambled DNA 50-CATGTAATCCGGCCCAGTCGA-30
50-ﬂank (9) DNA 50-CCGCCTCCC-30
30-ﬂank (10) DNA 50-GCGCATGGGA-30
7-2A-7 DNA 50-CATGGGAAACCGCCTC-30
8-2A-0 DNA 50-AACCGCCTCC-30
8-2A-1 DNA 50-AAACCGCCTCC-30
8-2A-2 DNA 50-GAAACCGCCTCC-30
8-2A-3 DNA 50-GGAAACCGCCTCC-30
8-2A-4 DNA 50-GGGAAACCGCCTCC-30
8-2A-5 DNA 50-TGGGAAACCGCCTCC-30
8-2A-6 DNA 50-ATGGGAAACCGCCTCC-30
8-2A-7 DNA 50-CATGGGAAACCGCCTCC-30
8-2A-8 DNA 50-GCATGGGAAACCGCCTCC-30
Linear (40) DNA 50-GCGCATGGGACGTGTGAAGGTACTCACACTGCCGCCTCCC-30
9-0A-10 RNA 50-GCGCAUGGGACCGCCUCCC-30
9-1A-10 RNA 50-GCGCAUGGGAACCGCCUCCC-30
9-2A-10 RNA 50-GCGCAUGGGAAACCGCCUCCC-30
9-3A-10 RNA 50-GCGCAUGGGAAAACCGCCUCCC-30
E10B RNA 50-UGAAGGUACUCACACUGCCGC-30
Scrambled RNA 50-CACGGAGACCCGAUUCGUCAU-30
50-ﬂank (9) RNA 50-CCGCCUCCC-30
30-ﬂank (10) RNA 50-GCGCAUGGGA-30
lys-4-1egl-4-8lys lysCGCCeglAGGG(lys)8
lys-5-1egl-5-8lys lysCCGCCeglAGGGT(lys)8
lys-6-1egl-6-8lys lysTCCGCCeglAGGGTA(lys)8
lys-7-0egl-7-8lys lysCTCCGCCAGGGTAC(lys)8
lys-7-1egl-7-8lys lysCTCCGCCeglAGGGTAC(lys)8
lys-7-2egl-7-8lys lysCTCCGCC(egl)2AGGGTAC(lys)8
lys-7-3egl-7-8lys lysCTCCGCC(egl)3AGGGTAC(lys)8
lys-8-1egl-8-8lys lysCCTCCGCCeglAGGGTACG(lys)8
lys-9-1egl-9-8lys lysCCCTCCGCCeglAGGGTACGC(lys)8
BACE1 50-splice site antisense RNA 50-GUUCCUCUCACCCUGGCAAUC-30
BACE1 30-splice site antisense RNA 50-GGAGUCGUCAGGCUUUGGCAG-30
RNA antisense molecules were modiﬁed with 20-OMe groups and a phosphorothioate backbone.
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an RNA ASO designed against the unfolded sequence at
the exon 10–intron 10 junction (21 nts, from G 7 to A+13)
also bound to the tau hairpin RNA, resulting in mobility
shift (lane 5), whereas a scrambled RNA molecule did not
hybridize (lane 6). A time course of binding showed a
slower hybridization of E10B against the unfolded struc-
ture compared with RNA 9-2A-10 binding to the discon-
tinuous region of the folded RNA, again suggesting that
the equilibrium favors the hairpin structure under these
assay conditions (Figure 2B and C). RNA ASO designed
against only the 50-ﬂank was able to hybridize (Figure 2A,
lane 7). Interestingly, in contrast to its DNA counterpart,
RNA ASO directed only to the 30-ﬂank did show partial
hybridization (lane 8), consistent with RNA:RNA hybrids
having stronger binding afﬁnity than RNA:DNA hybrids
(15). Where these 50- and 30-directed RNA ASOs are
included together in the hybridization reaction, both hy-
bridize almost completely (lane 9), resulting in a band
with slower mobility than the tau RNA hybridized to the
Figure 1. Complementary bipartite ASOs can bind to the discontinuous sequences that ﬂank the tau hairpin. (A) Diagram showing predicted RNA
folding at the exon 10 (uppercase, blue): intron 10 (lowercase, red) boundary to form a hairpin secondary structure. The design of a bipartite ASO
against the sequences ﬂanking the hairpin is shown underneath in black. (B) EMSA to show the extent of hybridization of DNA ASOs to the tau
hairpin-containing RNA sequence. ASOs were designed against the discontinuous sequences that ﬂank the hairpin or against the unfolded linear
sequence. A scrambled sequence was also tested. (C) EMSA showing the extent of hybridization of DNA ASOs designed separately against the
50- and 30-regions that ﬂank the tau hairpin RNA. Note that unhybridized 50-ﬂank ASO is too small to be detected. (D) EMSA revealing the
importance of binding of the 30-ﬂank. The hybridization of DNA ASOs with 7 or 8 bases complementary to the 50-ﬂank, and 0–8 bases comple-
mentary to the 30-ﬂank was examined.
9840 Nucleic Acids Research, 2012,Vol.40, No. 1950-directed or 30-directed ASO alone. This result is further
evidence that bipartite ASOs bind to the 30-ﬂank and
suggests that the 30-ﬂank of the tau RNA becomes more
available for ASO binding when the 50-ﬂank is also
hybridized. Bipartite RNA ASOs can also bind to tau
RNA with mutations that remove all complementarity in
the hairpin (Supplementary Figure S3). This result suggests
that while these ASOs bind to the discontinuous regions
ﬂanking the hairpin when the structure is present, they can
also bind when the structure is absent, looping out the
intervening non-complementary sequence as previously
reported with other bipartite ASOs (16,17).
Bipartite PNA ASOs were also studied by EMSA
(Figure 2D). These PNA ASOs contain linkers comprised
of 0–3 ethylene glycol (egl) units, and one egl was found to
be optimal for binding to the tau hairpin RNA
(Supplementary Figure S4). PNA ASOs as short as 4 com-
plementary bases on each side result in some hybridization
to the tau RNA (lane 2), and the extent of hybridization
increases with ﬂank length. Since a DNA ASO composed
of seven complementary nucleotides on each side could
not hybridize, these RNA:PNA duplexes must have
stronger binding afﬁnity than RNA:DNA duplexes, con-
sistent with what is known of RNA:PNA hybrids in
general (15). Taken together, the EMSA results show
that bipartite DNA, RNA and PNA ASOs can bind the
tau hairpin-containing RNA.
Bipartite ASOs bind to both ﬂanking regions of the tau
hairpin RNA
To show that these ASOs were binding where predicted,
RNase protection assays were performed. In these experi-
ments, a 50-biotinylated version of the 40-nt synthetic tau
RNA was tethered to streptavidin agarose beads and sub-
jected to RNase A or T1 digestion in the absence or
presence of DNA ASO 9-2A-10. 50 biotinylated cleavage
fragments were then analyzed by denaturing urea/acryl-
amide gel electrophoresis. The degradation proﬁle of the
tau RNA alone by RNase A, which cleaves 30 of unpaired
C and U residues, shows cleavage sites at C+25, U+23 and
C+21 (in the 30 ﬂank), at C+12 (on the 30 side of the stem)
and at C-3 (on the 50 side of the stem) (Figure 3A, lane 3).
A predominant band is seen at U+6, which is found in the
Figure 2. RNA and PNA complementary ASOs can bind to the discontinuous sequences that ﬂank the tau hairpin. (A) The extent of hybridization
of RNA ASOs to the tau hairpin-containing RNA was tested by EMSA. Modiﬁed RNA does not stain with SYBR Gold, so bands representing
unhybridized RNA ASOs are not seen on the gel. (B) EMSA showing the time-course of hybridization of 9-2A-10 and E10B RNA ASOs to the tau
hairpin RNA. (C) Quantiﬁcation of the intensity of the tau RNA band. Data are the mean± S.E.M. from three independent experiments,
normalized to the intensity of tau hairpin RNA alone. (D) EMSA showing the effect of increasing ﬂank length of PNA ASOs on the extent of
hybridization with the tau hairpin-containing RNA. PNA ASOs also contain lysine residues to aid cell penetration for experiments beyond the scope
of the current study.
Nucleic Acids Research, 2012,Vol.40, No. 19 9841loop region. That the main cleavage event occurs at U+6
(and that this base must therefore be unpaired) lends
further evidence for the hairpin structure, which has
been described for a 25-nt RNA by nuclear magnetic res-
onance (NMR) spectroscopy (18) but is seen here for the
ﬁrst time in the presence of additional ﬂanking sequences.
In the presence of DNA ASO 9-2A-10, bands at C+25,
U+23 and C+21 were reduced (lane 4), indicating that this
region of RNA is protected from RNase A by hybridiza-
tion to the bipartite DNA ASO. The degradation proﬁle
produced by RNase T1, which cleaves unpaired G
residues, revealed predominant cleavage sites are at
G+26 and G+24 (in the 30-ﬂank) and at G+5 (in the
loop) (Figure 3B). Pre-treatment with DNA ASO
9-2A-10 results in a robust decrease of RNase T1
cleavage at G+24 and interestingly, promotes digestion
within the loop region. Cleavage at G+26 may also be
blocked, but the resolution between this band and the
full-length RNA was not sufﬁcient to determine this.
These results are in good agreement with the RNase A
footprinting results and with the proposed model of the
RNA secondary structure (18). In addition, these results
provide evidence that the 30-ﬂanking region is indeed
bound by the bipartite DNA ASO.
RNase H is a nuclease which digests RNA only where it
is hybridized with DNA, leaving the DNA and
unhybridized regions of RNA intact. After digestion of
the tau RNA:50-ﬂank-directed DNA ASO hybrid by
RNase H (Figure 3C, lane 7), the remaining RNA is
shorter than in its full length form (lane 2), indicating
that the region bound by the 50-ﬂank-directed DNA has
been degraded. When the RNA is hybridized to the
30-ﬂank-directed DNA, RNase H digestion occurs (lane
8), although the remaining fragment is not as short as
expected, suggesting that the 30-ﬂank is incompletely
bound, possibly due to involvement in further secondary
structure. Additionally, some undigested full-length
RNA remains, which may indicate that this reaction
does not proceed as quickly as the digestion of the
RNA:50-ﬂank-directed DNA hybrid. When both 50- and
30-ﬂank-directed DNA ASOs are bound to the tau RNA
before RNase H digestion (lane 9), the remaining RNA is
shorter than the fragment left after digestion with 50-o r
30-ﬂank-directed DNA alone, and this RNA fragment is
the same size as that seen after digestion of the hairpin
RNA:9-2A-10 hybrid (lane 10). This result again suggests
that ASO binding to the 50-ﬂanking region makes the
30-ﬂanking region more accessible and gives further
support to the hypothesis that when the tau RNA is
hybridized with 9-2A-10, both 50- and 30-regions ﬂanking
the hairpin are bound to the bipartite ASO.
Bipartite ASOs alter tau pre-mRNA in vitro splicing
We next sought to address whether the binding of bipart-
ite ASOs across this discontinuous region would stabilize
the secondary structure sufﬁciently to inhibit exon 10
splicing. To this end, we designed an in vitro splicing
assay to assess exon 10 splicing in a cell-free environment.
The splicing unit RNA comprised exon 10, a shortened
intron 10 and exon 11. The splicing unit RNA was
incubated with nuclear extract from HeLa cells to allow
the splicing machinery to recognize and remove intron 10,
and products were detected by RT–PCR. As shown in
Figure 4A, reactions containing both tau splicing unit
RNA and HeLa nuclear extract lead to a band near the
expected 179 bp of the correctly spliced product (lane 4),
whereas tau RNA or HeLa nuclear extract alone do not
(lanes 2 and 3, respectively). The splicing efﬁciency of our
system is apparently quite low, as RT–PCR is needed to
detect the spliced product, and large smears for unspliced
products are seen in all lanes with splicing unit RNA, re-
gardless of the presence of nuclear extract. Nevertheless,
the presence of the spliced product is clear, and the ability
of ASOs to block its formation can be assessed. Upon
inclusion of 9-1A-10 RNA antisense, this band becomes
less intense in a concentration-dependent manner (lanes 5–
10). This antisense effect is sequence-speciﬁc since a
scrambled RNA at the highest concentration tested
(1mM) had no inhibitory activity on exon 10 splicing
(lane 11). cDNA reverse transcribed from RNA from
SK-N-SH cells transfected with the splicing unit vector
served as a positive control for the correctly spliced
product (lane 12). Because antisense oligonucleotides can
inhibit reverse transcription (19–22), a control experiment
was performed during which 9-1A-10 RNA antisense
(1nM–1mM) was included in the reverse transcription
step. There was no block of reverse transcription of the
spliced product (unsurprising, as half of this bipartite ASO
is targeted to an intronic sequence) (Supplementary Figure
S5), indicating that the effect of 9-1A-10 RNA antisense is
due to inhibition of splicing.
Since an aberrant increase in exon 10 splicing is a
feature of certain FTD-causing tau mutations, we
examined whether this bipartite ASO strategy would
also be effective in inhibiting exon 10 splicing from a
hairpin that is destabilized by such a mutation. The
DDPAC mutation (a C to T mutation at position +14
after the exon 10–intron 10 boundary) was introduced
into the splicing unit RNA. A comparison of the wild-
type and DDPAC splicing units (Figure 4B, lanes 4 and
5) revealed increased exon 10 splicing for the DDPAC
splicing unit, in agreement with previous reports
(8,10,11,23). Exon 10 splicing from the DDPAC splicing
unit RNA could also be inhibited by inclusion of RNA
ASO 9-1A-10 in the splicing reaction (lanes 6–11), but not
by a scrambled RNA (lane 12). Collectively, these results
provide evidence that bipartite ASOs can bind to the dis-
continuous regions that ﬂank the tau mRNA hairpin and
inhibit exon 10 splicing in a cell-free system.
Bipartite ASOs alter tau pre-mRNA splicing in cells
We next determined whether these RNA ASOs could
inhibit exon 10 splicing from a tau minigene (11,23) in
SK-N-SH neuroblastoma cells. The splicing pathway for
this minigene is depicted in Figure 5A. The minigene was
transfected alone or co-transfected with 9-1A-10, E10B or
a scrambled RNA ASO, and exon 10 splicing was assessed
by exon-trapping PCR. E10B is an antisense RNA com-
plementary to the linear sequence of the splice site of the
unfolded exon10–intron 10 boundary and has been
9842 Nucleic Acids Research, 2012,Vol.40, No. 19Figure 3. RNase digestion proﬁles of the 50-biotinylated tau hairpin-containing RNA with bound DNA ASO. (A) RNase A 50-digestion fragments of
tau hairpin-containing RNA with and without protection by bipartite 9-2A-10 DNA. Digestion fragments were run alongside an alkaline hydrolysis
ladder of all possible 50-biotinylated fragments and alongside undigested RNA. Bands representing cleavage in the 50-ﬂank (below C 3) are too small
to be resolved or detected on the gel. (B) RNase T1 digestion proﬁle of the tau RNA as in panel A. (C) RNase H digestion of the tau RNA when
bound to DNA ASOs. Digestion products were analyzed by denaturing urea/acrylamide gel electrophoresis and visualized by SYBR Gold staining
under UV light.
Nucleic Acids Research, 2012,Vol.40, No. 19 9843Figure 4. In vitro splicing of a tau splicing unit comprising exon 10, a shortened intron 10 and exon 11 in the absence or presence of a bipartite RNA
ASO. Products from the in vitro splicing reactions were puriﬁed by phenol/chloroform precipitation and ampliﬁed by reverse transcription PCR.
Unspliced RNA and spliced products were visualized by 8% acrylamide gel electrophoresis and SYBR Gold staining under UV light. In vitro splicing
of a wild-type tau splicing unit (A) and a tau splicing unit containing the FTDP-17-associated DDPAC mutation (B) was inhibited by 9-1A-10 RNA
in a concentration-dependent manner.
9844 Nucleic Acids Research, 2012,Vol.40, No. 19previously shown to be effective in decreasing exon 10
splicing from a tau minigene (11,24). In cells transfected
with the minigene alone, exon 10 was predominantly
excluded, and the PCR product representing 3R tau was
more intense than the PCR product representing 4R tau
(Figure 5B, lanes 2 and 3). This deviation from the
expected 1:1 ratio of 3R:4R tau that is seen in healthy
adult brain may be due to a number of reasons (e.g. dif-
ferent 50- and 30-UTRs, shortened introns, absence of
other exons, heterologous overexpression in undifferenti-
ated neuroblastoma cells). Upon co-transfection with
10nM RNA ASO 9-1A-10, the expression of the
isoform representing 4R tau (in which exon 10 is
included) was decreased (lanes 4 and 5). Faint additional
Figure 5. The effect of RNA ASOs on alternative exon splicing from a tau minigene and from a BACE1 minigene expressed in SK-N-SH cells.
(A) Diagram of alternative splicing pathways of a minigene encoding tau exons 9, 10 and 11. (B) Exon-trapping PCR from the wild-type minigene
co-expressed with 9-1A-10, E10B, scrambled RNA antisense or no antisense in SK-N-SH cells. PCR products were analyzed by 8% acrylamide gel
electrophoresis and SYBR Gold staining under UV light. (C) Exon-trapping PCR from the DDPAC minigene expressed in SK-N-SH cells. (D) RNA
ASOs against the 50-o r3 0-ﬂank of the tau hairpin (alone or in combination) have no effect on splicing from the wild-type or DDPAC (E) minigene.
(F) Diagram of alternative splicing pathways of a minigene encoding BACE1 exons 3 and 4. (G) Exon-trapping PCR from the BACE1 minigene.
Nucleic Acids Research, 2012,Vol.40, No. 19 9845bands at  220bp are also seen which, according to in
silico predictions, likely represent splicing from a cryptic
donor splice site in intron 9. Co-transfection of the
wild-type minigene with RNA ASO E10B resulted in a
similar decrease of 4R tau (lanes 6 and 7).
Co-transfection with a scrambled antisense did not alter
the pattern of splicing compared with the tau minigene
transfected alone (lanes 8 and 9).
As with the in vitro splicing experiments, we next sought
to determine whether bipartite ASOs could inhibit exon 10
splicing from a tau minigene containing a hairpin-
destabilizing FTD mutation (Figure 5C). In cells trans-
fected with the DDPAC minigene alone (lanes 2 and 3),
the ratio of 3R:4R was shifted in favor of the 4R isoform
in contrast to the wild-type minigene, as predicted and
previously demonstrated (8,10,11,23). Co-transfection of
bipartite RNA ASO 9-1A-10 (lanes 4 and 5), targeted to
the regions ﬂanking the hairpin, or E10B RNA (lanes 6
and 7), targeted to the exon–intron junction, both resulted
in correction of the splicing defect by decreasing the 4R
and increasing the 3R isoforms. Co-transfection of the
DDPAC minigene with a scrambled RNA (lanes 8 and
9) resulted in a splicing proﬁle similar to that seen from
the minigene transfected alone. RNA ASOs targeted to
only the 50-ﬂanking region or only the 30-ﬂanking region
did not alter the splicing proﬁle of the wild-type or
DDPAC tau minigene, and neither did the combination
of these two ASOs (Figure 5D and E). This result reveals
the importance of connecting the two ASOs into a single
bipartite ASO, in order to simultaneously bind the discon-
tinuous regions that ﬂank the hairpin and thereby inhibit
exon 10 splicing. However, the presence of the hairpin is
not necessary for the bipartite RNA ASOs to alter
splicing, as simultaneously disrupting ﬁve hairpin base
pairs with FTD-associated mutations still allow these
ASOs to shift splicing from 4R to 3R tau
(Supplementary Figure S6). These results are consistent
with the EMSA experiments described earlier, showing
that disruption of the hairpin complementarity still
allowed RNA ASO binding. The speciﬁcity of the bipart-
ite ASOs for tau exon 10 was conﬁrmed using a minigene
encoding exons 3 and 4 of b-site APP cleaving enzyme
(BACE1, Figure 5F) (13). Upon transfection of this
minigene alone, variant A is the predominant isoform
(Figure 5G, lanes 2 and 3); with much lower expression
of variants B and C. This splicing proﬁle is largely un-
changed upon co-transfection with RNA ASO 9-1A-10
(lanes 4 and 5) with the exception of a small increase in
isoform B. However, co-transfection with either of two
different RNA ASOs complementary to the BACE1
minigene 30-splice site (lanes 6 and 7) or 50-splice site
(lanes 8 and 9) resulted in the expected substantial alter-
ations of the splicing proﬁles. RNA ASO 9-1A-10 was also
found to have no effect on splicing from minigenes for
SMN1, SMN2, ApoA-II and Casp3 (Supplementary
Figure S7A, B).
The effect of the RNA ASO 9-1A-10 was further
examined by quantitative real-time PCR. In order to
compare the approaches of targeting the exon–intron
junction with RNA ASO E10B, and targeting the
regions ﬂanking the hairpin with RNA ASO 9-1A-10,
we quantiﬁed the expression of 4R and 3R transcripts
from tau minigenes co-expressed in SK-N-SH cells with
these antisense molecules (Figure 6). 4R tau was ampliﬁed
using a forward primer across the exon 9–exon 10 bound-
ary, whereas 3R tau was ampliﬁed by using a forward
primer across the exon 9–exon 11 boundary. Compared
with a scrambled RNA ASO, 10nM 9-1A-10 or E10B
signiﬁcantly reduced expression of 4R tau from the
wild-type minigene by 68 and 66%, respectively. In
addition, 10nM 9-1A-10 and E10B signiﬁcantly increased
expression of 3R tau by 37 and 65%, respectively
(one-way ANOVA with post-hoc Bonferroni’s test,
P<0.05) (Figure 6A). Similar results were obtained for
the DDPAC tau minigene; co-transfection of the
DDPAC minigene with 10nM 9-1A-10 or E10B signiﬁ-
cantly reduced expression of 4R tau by 57 and 61%, re-
spectively with concomitant increase in 3R tau expression
(a 4-fold increase in both cases) (Figure 6B). These results
are in good agreement with the exon trapping PCR data.
The effect of 9-1A-10 was also shown to be
concentration-dependent (Figure 6C). At these bipartite
ASO concentrations, the total tau was not altered
(Figure 6D).
Finally, we sought to inhibit exon 10 splicing from en-
dogenous tau pre-mRNA. Due to the low endogenous
expression of tau mRNA in SK-N-SH neuroblastoma
cells, HEK-293 cells, which have higher tau expression,
were used for these experiments. Cells were transfected
with 0–1mM antisense RNA, and the expression of total
tau, 3R and 4R tau was analyzed after 24h by real-time
PCR. Transfection of cells with RNA ASOs 9-1A-10 or
E10B resulted in a signiﬁcant reduction in 4R tau (42 and
45% reductions, respectively) compared with cells trans-
fected with a scrambled RNA ASO (Figure 6E). The con-
comitant increase in 3R tau was not statistically
signiﬁcant, possibly due to high expression of the 3R
isoform compared with the 4R isoform in these cells
(23). There was no change in the levels of total tau
mRNA when normalized to the expression of GAPDH
for any of the transfections, indicating that this was a
speciﬁc effect on exon 10 splicing (Figure 6F). The bipart-
ite RNA ASO showed a maximum effect of a 42% reduc-
tion of exon 10 splicing at 1mM (Figure 6E); the inhibition
is not complete even at this high concentration of RNA
ASO, likely due to imperfect transfection efﬁciency. This
ASO is speciﬁc for tau since it had no effect on splicing of
the endogenous IG-20 gene in SK-N-SH cells
(Supplementary Figure S7C). Taken together, these
results demonstrate that a bipartite ASO designed to
target the regions ﬂanking the hairpin structure at the
exon 10–intron 10 boundary is effective in speciﬁcally in-
hibiting exon 10 splicing from a tau minigene and from the
endogenous tau pre-mRNA in cell culture.
DISCUSSION
Antisense technology is an important alternative to small
molecules and proteins for manipulating biological
systems (15), and in contrast to RNA interference, anti-
sense approaches allow more varied effects than simply
9846 Nucleic Acids Research, 2012,Vol.40, No. 19knocking down the target of interest. Among these effects
is modulation of RNA splicing, which allows skipping of
exons with premature stop codons, changing the propor-
tions of protein isoforms, or shunting toward isoforms
that undergo nonsense-mediated decay. Typical antisense
design involves directly blocking splice sites or regulatory
elements with an ASO complementary to the linear
mRNA sequence (25). It is generally thought that target-
ing secondary structures should be avoided, as structures
such as hairpins can interfere with ASO binding (26).
However, structural features in mRNA can have import-
ant functions, including the regulation of alternative
splicing (4), and strategies for targeting these structured
regions should be developed. Here, we have focused on a
hairpin motif in the pre-mRNA of the microtubule-
associated protein tau as a proof of principle that target-
ing such structures with ASOs to promote alternative
splicing is possible.
The ratio of 3R to 4R isoforms of tau, resulting from
the exclusion or inclusion of exon 10, respectively, is ap-
proximately 1:1 in the adult human brain. Altering the
balance of these isoforms can cause disease, as silent or
intronic mutations in the tau gene that are associated with
frontotemporal dementia increase the 4R-to-3R ratio
from the normal 1:1 balance (8,9). Such alteration of tau
splicing is sufﬁcient for the development of tau pathology
in the brain and dementia in mid-life. The inclusion or
exclusion of exon 10 is controlled in part by a hairpin
structure at the boundary between exon 10 and intron
10. Self-complementarity in this region was ﬁrst noted
upon initial discovery of genetic mutations in tau
associated with FTD (8,9). A number of these disease-
causing mutations disrupt the hairpin self-
complementarity and thereby increase the proportion of
4R tau (7). In contrast, designed mutations that increase
self-complementarity in this region, stabilizing the hairpin
structure, increase the proportion of 3R tau (11). Indeed,
the exclusion of exon 10 correlates with the stability of the
hairpin structure (11). Further evidence for the hairpin
structure is provided in this study, in which we show
that the stem region of the tau hairpin is protected from
RNase degradation, with cleavage occurring in the
single-stranded loop region.
To target the hairpin of the tau pre-mRNA, we
designed bipartite ASOs to interact simultaneously with
the regions that ﬂank either side of this structure. The
two antisense stretches were connected in a single ASO,
so that simultaneous binding to the 50- and 30-ﬂanking
regions could take place in the presence of the hairpin
structure. A similar strategy had been reported from the
laboratory of Alanna Schepartz (27–29), in which
‘tethered oligonucleotide probes’, linking two oligonucleo-
tides through a polyethylene glycol spacer, were designed
to interact with sequences ﬂanking RNA structural motifs;
i.e. these tethered oligonucleotides were targeted to struc-
ture, as well as sequence. Another report describes DNA
aptamers that bind an engineered RNA hairpin and
thereby inhibit in vitro translation when this artiﬁcial
hairpin is inserted into a 50-untranslated region (30). In
addition, a recent report describes the design of oligodeox-
yribonucleotides against discontinuous regions of RNA to
Figure 6. Bipartite RNA ASO inhibits exon 10 splicing from a tau
minigene expressed in SK-N-SH cells and from the endogenous tau
pre-mRNA in HEK-293 cells, as quantiﬁed by real-time PCR. 10nM
9-1A-10 RNA or E10B RNA caused a signiﬁcant reduction in exon 10
splicing from the wild-type minigene (A), and from the DDPAC
minigene (B), with a concomitant increase in the 3R isoform
compared with 10nM scrambled control RNA. (C) The inhibition of
exon 10 splicing by 9-1A-10 RNA was concentration-dependent, with
an IC50 of 5.4nM. (D) 9-1A-10 RNA ASO does not alter total tau
expression from the tau minigene in SK-N-SH cells. Total tau expres-
sion from the minigene in transfected cells was normalized to the ex-
pression of pRL-TK, which was used as a transfection control. (E)
Transfection of HEK-293 cells with 1mM 9-1A-10 or E10B antisense
RNA signiﬁcantly inhibits exon 10 splicing from the endogenous tau
pre-mRNA in comparison with transfection with a scrambled control.
(F) Total endogenous tau is unaltered in cells transfected with 1mM
9-1A-10, E10B or scrambled RNAs. Expression of total tau was
normalized to expression of GAPDH.
Nucleic Acids Research, 2012,Vol.40, No. 19 9847induce bulges in order to study the action of ribonuclease
mimics (16,17). However, the current work is the ﬁrst
demonstration to our knowledge of the use of a bipartite
ASO to target a naturally occurring RNA secondary
structure in order to modulate alternative splicing.
EMSAs demonstrated that bipartite ASOs do indeed
bind to an RNA oligonucleotide representing the normal
human tau hairpin motif and ﬂanking sequences, that this
binding requires both parts of the designed ASO and 1:1
stoichiometry. RNase digestion experiments conﬁrmed ef-
fective binding to the 30-ﬂanking region, as this region was
protected in the presence of a bipartite DNA ASO.
Bipartite ASOs also decreased the splicing of exon 10,
both in vitro and in cells, with wild-type and
FTD-mutant tau minigenes, and with endogenous tau as
well. Notably, the bipartite ASO does not inhibit the
correct splicing of exon 9 to exon 11 (to generate the 3R
tau isoform), nor does it inhibit normal or alternative
splicing of control minigenes. The bipartite ASO also ef-
fectively reduced the level of the endogenous 4R tau
isoform without altering total endogenous tau mRNA.
Taken together, these results indicate that the designed
bipartite ASOs block tau exon 10 splicing by simultaneous
binding to the 50- and 30-regions that ﬂank the hairpin
structure at the boundary between exon 10 and intron
10. Neither half of the bipartite ASOs binds as effectively
as the bipartite ASOs themselves, and both halves of the
bipartite sequence are required for inhibition of exon 10
splicing. By virtue of their bipartite nature, these ASOs
can bind to tau pre-mRNA in the presence of the
hairpin structure.
We believe this is the ﬁrst demonstration that bipartite
ASOs can target a structural motif in a pre-mRNA and
thereby inhibit splicing. We have shown this strategy to be
as effective for inhibition of splicing as directly blocking
the linear sequence at the splice site. Targeting secondary
structure to modulate splicing rather than binding directly
to splice sites or regulatory sequences may be a useful
strategy to improve speciﬁcity, given the degree of consen-
sus of splice site and regulatory sequences. Recently, we
reported a small molecule, mitoxantrone, that binds to
and stabilizes the tau hairpin structure (31). The site of
mitoxantrone interaction in the hairpin is located near the
base of the stem, proximal to where the bipartite ASOs
bind (32). Thus, it should be possible to connect this
compound to bipartite ASOs through the linker region,
to form tripartite agents that simultaneously bind the 50-
ﬂanking region, the 30-ﬂanking region, and the stem of the
hairpin with high potency and speciﬁcity. Such studies are
presently underway.
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